By Notice dated October 25, 2002, and published in the Federal Register on November 7, 2002, (67 FR 67870), Abbott Laboratories, DBA Knoll Pharmaceutical Company, 30 North Jefferson Road, Whippany, New Jersey 07981, made application by renewal to the Drug Enforcement Administration to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:
The firm plans to manufacture bulk product and finished dosage units for distribution to its customers.
No comments or objections have been received. DEA has considered the factors in title 21, United States Code, section 823(a) and determined that the registration of Abbott Laboratories, DBA Knoll Pharmaceuticals, to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Abbott Laboratories, DBA Knoll Pharmaceuticals, to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.Start Signature
Dated: April 7, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 03-10397 Filed 4-25-03; 8:45 am]
BILLING CODE 4410-09-M